27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Among 2144 participants (540 deaths over a median 4.4 years of survivor follow-up; 25% mortality), the seven-marker score plus age and sex achieved an apparent C of 0.74 (optimism-corrected 0.74), versus 0.68 for age and sex alone (Δ ≈ 0.06); the blood panel alone reached C 0.72. 2 key findings →
Design: longitudinal study Participants: 2,144 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The SPICT-TR is a culturally adapted, valid, and reliable assessment tool for identifying patients with palliative care needs within the Turkish healthcare system. 4 key findings →
Participants: 356 Evidence: low
Full summary, score breakdown and related studies → Original source
We included 23 studies with qualitative (73.9%) or quantitative/mixed-methods (26.1%) designs. 5 key findings →
Design: longitudinal study Participants: 23 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Forty‑two studies published between 1997 and 2025 were included. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Polypharmacy and PIMs are highly prevalent in end-of-life elderly cancer patients. 3 key findings →
Design: cross-sectional Participants: 183 Evidence: low
Full summary, score breakdown and related studies → Original source
This nationwide study provides epidemiological data on dementia and MCI among adults aged ≥ 60 years across all 12 administrative regions of Morocco. 1 key finding →
Design: cross-sectional Participants: 1,662 Evidence: low
Full summary, score breakdown and related studies → Original source
This study reports the prevalence of CF among elderly hypertensive residents of a community in Inner Mongolia. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Drama therapy is in an accelerated growth phase, with substantial scholarly expansion expected over the next two decades. 4 key findings →
Participants: 785 Evidence: high
Full summary, score breakdown and related studies → Original source
We found opposite effects of age on FMAR at both short and long time scales, respectively (ßAge=0.014, 95% C.I. [0.009,0.019] and ßAge=-0.015, 95% C.I. [-0.026,-0.005]), as well as differences between women and men at long time scales (ßSexMen=+0.028, 95% C.I. [0.012,0.044]). 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this setting, selective participation had only a limited effect on prevalence estimates after weighting. 2 key findings →
Participants: 25,977 Evidence: low
Full summary, score breakdown and related studies → Original source
Base-case incremental cost-effectiveness ratios (ICERs) for lecanemab versus standard of care were €296,506 per QALY gained, and €371,299 per QALY for donanemab, from the HSE payer perspective under HIQA guidelines. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Sociodemographic and clinical variables routinely recorded in PC EHRs may contribute to dementia identification. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Symptom chronology emerged as a robust diagnostic discriminator, underscoring the clinical value of temporal disease trajectories. 3 key findings →
Participants: 932 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer’s disease (AD) is a neurodegenerative disorder that is characterized by structural changes of the hippocampus, thus hippocampal morphology becomes an important biomarker for early diagnosis. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Implementation of an EHR-enabled AD care pathway was associated with improved adoption of guideline-concordant cognitive assessment and recommended diagnostic evaluation in primary care across three health systems. 5 key findings →
Participants: 10,206 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia public stigma was associated with education, dementia knowledge, media exposure, chronic diseases, and contact experience with people living with dementia. 5 key findings →
Design: cross-sectional Participants: 3,055 Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with MCI and AD exhibit marked deficits in the performance and accuracy of upper-limb reaching and catching movements when assessed in a VR environment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Medication adherence in older adults was strongly influenced by cognitive impairment, gender, health literacy and cohabitation. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
The retina displayed earlier and broader AD-related molecular alterations than the hippocampus. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Functional–behavioral subtypes can be identified in hospitalized AD patients, supporting multidimensional risk stratification and individualized care planning. 2 key findings →
Design: cross-sectional Participants: 118 Evidence: low
Full summary, score breakdown and related studies → Original source
Thorough and structured assessment is essential for identifying unmet needs and managing distress in people with dementia in acute hospitals. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Nurses showed moderate knowledge and positive attitudes, with knowledge closely linked to attitudes. 3 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Significant positive correlations were observed among pain, cognitive impairment, agitation, and neuropsychiatric symptoms (all p < 0.001). 4 key findings →
Participants: 107 Evidence: low
Full summary, score breakdown and related studies → Original source
Brexpiprazole was associated with a distinct neuropsychiatric adverse-event reporting pattern in Alzheimer’s disease compared with psychiatric indications, with the most consistent signals observed for delirium, falls, and agitation. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Affective symptoms, such as depression, anxiety and apathy, are highly prevalent in cognitively impaired Lewy body disease (LBD) groups, including Parkinson’s disease dementia and dementia with Lewy bodies. 2 key findings →
Design: systematic review Participants: 785 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →